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Abstract:
Millions of people die each year from infectious diseases. This is partly due to the
difficulty of transporting

temperature

dependent vaccines through what is called the cold chain

in developing countries. I hypothesize that we can increase vaccine accessibility by finding cost
effective alternatives to vaccine production and by eliminating the cold chain through vaccine
stabilizers. The gold standard in purification of influenza virus is by means of
ultracentrifugation

. Although effective, this process is very expensive and thus impractical for

developing countries . I hypothesize that column chromatography
alternative that is as effective as ultracentrifugation
chromatography

can be a cost efficient

. The purification

ability of column

was tested by comparing two different chromatography

resins. The Capto Q

resin separates proteins on the basis of protein charge . The Capto 700 resin separates proteins
on the basis of both size and charge. It was found that while protein separation occurred, more
research will be required to assure full viral protein purification.

It is hypothesized that vaccine stabilizers can be used to eliminate the cold chain. The
effect of the gelatin on inactivated influenza virus vaccines was evaluated using hemagglutinin (HA)
assays and neuraminidase (NA) assays. The assays evaluate viral protein activity in samples exposed
to elevated temperatures for set periods of time (1 min, 5 min, 10 min, 20 min, 40 min, 60 min, 120
min, 240 min, 300 min, and 360 min). Elevated temperatures (45, 52, and 60 degrees Celsius)
facilitated an accelerated stability test, which simulates extended effects of time on vaccines. In
addition to testing different temperatures, the following concentrations of collagen were used as
percent by total volume: 0.3%, 1%, 3%, and 10%. These were tested for optimizing the stabilization
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of the vaccine . The results of the neuraminidase assay show that 3% collagen significantly increased
the stability of the vaccine by approximately 10,000 fold .
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Introduction
1.1 Background

It is estimated that 17 million people die each year from infectious diseases (Chen et al.,
2011) . This accounts for more than half of the deaths found in the poorest of developing
countries (Yager et al., 2006). While our medical technology is advancing, pandemics such as
HIV and Ebola are still rampaging through the developing world killing millions of people each
year. Many infectious agents such as anthrax and small pox pose threats that could be used as
weapons in bioterrorism. While antibiotics are used as a means of rescue, vaccines have been
considered one of the greatest medical advancements in preventing such diseases (Kumru et

al., 2014). While the need for vaccines is crucial, many do not have access to them .
The lack of vaccine accessibility is partially the result of 1) the cost of manufacturing,
and 2) the insufficiency of the transportation

cold chain. I hypothesize that vaccine accessibility

could be increased by addressing either of these two problems. By finding cost alternatives to
manufacturing, such as column chromatography, developing nations could find ways to
manufacture vaccines in their own country . If vaccines are manufactured on site , one could
eliminate the costs of transportation.

In addressing the insufficiency of the cold chain, I

hypothesize that gelatin could be used as a vaccine stabilizer thus eliminating the need for a
cold chain.
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1.2 Costs of Manufacturing

A vital step in vaccine production is the purification of the virus in the vaccine. Normally
this purification is done through ultracentrifugation.

While effective, ultracentrifugation

is

extremely expensive making it impractical for developing countries. Column Chromatography
is a purification alternative that is cost efficient. It is hypothesized that column
chromatography may be as effective as ultracentrifugation

and could be utilized in developing

countries for vaccine production.

We used the influenza A/NWS/33 (HlNl) virus to test the purification ability of column
chromatography. Madin Darby Canine Kidney (MDCK) cells were infected with virus, the virus
was then inactivated by means of Binary Ethyleneimine (BEi). To compare the purification
ability of column chromatography two different chromatography resins were used: Capto Q and
Capto 700.

Capto Q is a resin that separates
proteins on the basis of charge. This is
done by anion exchange . The Capto Q
resin uses a quaternary Amine group
that has a positive charge. This allows

Figure 1: Artistic portrayal of the Capto 700 resin.
Picture displays the ligand-activated core, as well as

proteins with a negative charge to bind

the outer membrane containing microscopic pores.
Small proteins (in purple and yellow) are able to bind

to the column allowing them to be

to the core while contaminants (shown in red) cannot
penetrate the outer shell

separated from the rest of the solution
http://wolfson.huji.ac.il/purification/PDF/HCIC/GE

flowing through the column.

CaptoCore700

DataFile.pdf

9

The second resin used was Capto 700 (Figure 1). This resin separates by size as well as
charge. It has the ability to separate both size and charge because the resin is composed of
beads that have a ligand-activated core and an outer layer that is composed of little
microscopic pores. The outer shell prevents large molecules from entering and binding to the
hydrophobic and positively charged ligands . Because both resins separate on the basis of
charge, elution buffers with a gradient of increasing salt concentrations were used for elution of
bound proteins.

1.3 Insufficiency of the Transportation Cold Chain

While vaccines are effective in preventing the spread of fatal diseases, they are
rendered useless if exposed to conditions outside of the optimal range. The World Health
Organization (WHO, 2006) has said that the only environmental factor to affect characteristics
of all vaccines is temperature . This is why vaccine transportation

relies so heavily on the cold

chain.

Zhang et al. (2012) defines the cold chain as the distribution network that strives to
keeps vaccines within the optimal temperature range during transport, storage, and handling.
This not only means keeping the vaccine from getting too warm , but also from freezing .
Vaccines contain molecules called adjuvants that increase the potency of the vaccine. Adjuvants
such as aluminum , however, are inactivated if frozen (Kumru et al., 2014). Accidental exposure
of vaccines to freezing temperatures during the length of the cold chain occurs in over 75% of
all shipments (Kumru et al., 2014) .
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The process of the cold chain can often be lengthy . Most vaccine cold chains start with
the manufacturer in a developed country. From there, the vaccine is typically flown to a central
store. This central store will house the vaccine for a t ime, after which it sends the vaccine to
regional stores, then to district stores , and finally to health clinics . Transportation between
locations can be via plane , car, or even foot. It is estimated that the total process can take
anywhere from 12- 18 months (Cheyne, 1989) . During this time the vaccines are housed in
refrigerators, cold boxes, or simply put on ice.

As manufacturers often send vaccines to remote areas of the world, the vaccines are
exposed to harsh climates and many unforeseeable challenges. Hurricanes , wars, or natural
disasters can delay shipments for extended periods of time. Power outages or lack of fuel often
render electric cooling units useless (Arya, 2000) . Many t imes vaccines are lost in international
flights , or central stores do not have room for them due to poor stock control (Cheyne, 1989). It
is foreseen that global climate change will only add to the difficulties in maintaining the stability
of vaccines (Arya , 2000). The logistics of the cold chain are often impractical in low resource
settings, and the costs often become a major burden to developing countries (Wolfson et al.,
2007).

The burden of the cold chain on vaccine programs accounts for $200-$300 million
dollars each year (Das, 2004) . This alone can contribute to 80% of the vaccine program's cost in
developing countries (Chen et al., 2011) . The money spent on simply transporting these vaccine
could vaccinate an additional 10 million children (Das, 2004). Countries impacted the most by
these costs are areas with harsher climates. Areas using kerosene powered coolers , can go
through half a liter of kerosene a day just to maintain temperatu res (Cheyne, 1989) .
11

Exposure to increased temperatures
Conformational

causes denaturation

of viral proteins.

changes of membrane proteins can cause the vaccine to lose its potency

decreasing its ability to elicit an immune response. These conformational

changes can also

cause the viral particles to aggregate, inactivating the vaccine (Zhang et al., 2012). The decrease
in vaccine potency requires an increase in dosages which in turn adds to the cost of vaccines for
developing countries (Chen et al., 2011). Zhang et al. (2012) estimates that failure of the cold
chain results in the loss of almost half of all global vaccines.

1.4 Use of Collagen as a Vaccine Stabilizer

Having seen the insufficiencies of the cold chain, I have hypothesized that collagen could
be used as a vaccine stabilizer thus eliminating the need for a cold chain. Collagen is a fibrous
structure that is made up of three parallel polypeptide strands (Shoulders et al., 2009). Collagen
is one of the most abundant structural proteins, and makes up one third of all total protein. It is
found in tendons, ligaments, vessels, as well as the extracellular matrix.

The polypeptide

strands of collagen typically consist of

three repeating sequences with glycine being every third
amino acid. The first two amino acids can vary, but the
sequence typically goes as follows: Xaa Yaa Gly (Shoulders et

Figure 2: Structure of the amino
acid Glycine
Photo taken from:

al., 2009) . Because of the abundance of glycine (Figure 2)

http ://www. mpbio .com/ product.php ?pid=O
4808822&country=223

each strand, known as the alpha chain, is tightly wrapped
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around itself. Three of these alpha chains

.i
Triple helix

1.4 nm form a helix (Figure 3} that is held

T
together by hydrogen bonding between
Q

Alpha chain

Amino acid

-

sequenoe - Gly - X - y - Gly - X - y - Gly - X - y Figure3: Structure of collagen fiber starting with the
amino acid sequence, alpha chain, and finally the
right handed triple helix. The triple helix is held
together by hydrogen bonding between the Glycine
and the X amino acid.
Photo taken from: http://www .namrata .co/categ ory/chemistry-ofprotein s/speci alized-protein-collagen/

the alpha carbon of Glycine and the
oxygen of the carbonyl group on the X
amino acid of the repeating sequence.
This causes a collagen strand to form a
right handed triple helix composed of
three left handed helical alpha strands,

with two hydrogen bonds within each amino acid triplet (Shoulders et al., 2009; Ottani et al.,
2001}.

In our experiment, collagen was used in the form of gelatin. Gelatin is denatured
collagen that was isolated from porcine skin. As Gelatin contains collagen strands of varying
lengths going in all directions, this causes a meshwork with micro pores hence becoming a gel
(Olsen et al., 2003}.

1.5 Structure of Influenza

Influenza A/California/07 /2009 (HlNl} virus and Influenza A/NWS/33 (HlNl} virus were
both used in our study. Influenza is an enveloped virus, meaning it is surrounded by a cell
membrane. This cell membrane makes influenza easy to kill, as one can disrupt the membrane
with ethanol or simple sanitizers . While this is convenient for sanitizing, it presents a difficulty
in stabilizing an influenza vaccine, as it is so easily disrupted. Inside the cell membrane are 8
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single stranded negative sense RNA segments that encode 11 different proteins (Kumru et al.,
2014). The virus is spherical in shape, and is typically 80-120 nm in diameter.

There are three different types of influenza viruses: A, B, and C. Influenza A and Bare
the types that are most associated with the annual or "seasonal" flu. These are further broken
down into subcategories depending on the glycoproteins that are found on the outer cell
membrane. Two of these membrane proteins were used in our assays to determine the vaccine
potency. The two membrane proteins are: hemagglutinin, and neuraminidase.

Hemagglutinin (HA) and
Influenza

Virus

neuraminidase (NA) are the structural

Anatomy

proteins that often elicit an immune
Lipid
Envelope

- Neuramlnldase
(Slalldase)

response in our bodies. These proteins
are often variable with 18 discovered HA
subtypes and 9 NA subtypes. Influenza
utilizes mutational drift to constantly

Figure 4: Structure of Influenza HlNl. Virus is

change these membrane proteins,

enveloped with 8 single stranded RNA molecules.
Membrane proteins shown in blue are
neuraminidase, and proteins shown in red are
hemagglutinin.

making it necessary for us to get flu shots
annually. A dramatic change in the

Photo taken from:
http://micro .magnet.fsu.edu/cells/viruses/influenzavirus.html

hemagglutinin antigen is less frequent; however, changes in this protein are often responsible
for larger pandemics (Kumru et al., 2014).

We classify the flu by using HxNx to specify which subtypes are found on the membrane.
Example Influenza A H1N1 contains HA subtype 1 and NA subtype 1. Vaccines use inactivated
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viruses with these membrane proteins intact in order to elicit an immune response (Pushko et

al., 2005}.
The membrane protein HA is a trimer composed of two
Putativo RBS

different domains: HA1 and HA2 (Figure 5}. HA has a head,
which binds to sialic acid found on receptors of the cells within
the body. These cells then engulf the virus via endocytosis.
Once inside the cell as an endosome, the virus utilizes a
channel that lowers the pH of the endosome. The lowering of
the pH causes a conformational change to occur in HA. After
the conformational change, hemagglutinin unfolds on itself
and exposes a part of the protein that bursts the endosome.
This releases the viral RNA into the cell (Skehel et al., 2000).
HA also binds to red blood cells causing them to agglutinate.
This allows us to quantify the amount of HA in a sample, by

Figure 5: Structure of

hemagglutinin protein. Blue
area represents HA2domain
and purple represents HA1
domain.
Photo taken from :
http ://sbkb .org/update/research/virolo
gy-a-bat-influenza-hemagglutinin

simply mixing them with red blood cells.

Once the virus has replicated and undergone self-replication, the virus leaves the cell via
exocytosis. Upon leaving the cell, however, the HA again binds to the host cell membrane and
cannot leave. The enzyme neuraminidase (NA) frees the virus by cleaving the sialic acid on the
cell membrane. This frees the virus allowing it to find another cell to infect. NA inhibitors, such
as Oseltamivir (also known as Tamiflu), prevent the cleavage of sialic acid. While this does not
stop the virus from initially infecting the cell, it prevents the virus from spreading to other cells.
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1.6 Accelerated Stability Test

As real time tests can take up to two years, we employed an accelerated stability test
for our experiment. Accelerated stability tests assess the rate of change of vaccine potency over
time by exposing the vaccine to increased temperatures that are above the normal storage
conditions. While accelerated stability tests cannot be used to estimate real time, they provide
important information

regarding the stability and vaccine potency (WHO 2006).

Methods and Materials
2.1 Virus

Influenza A/NWS/33 (HlNl)

virus was used for our column chromatography tests .

Influenza A/California/07 /2009 (HlNl)

was the virus used for the accelerated time tests. Both

viruses were provided by the Centers for Disease Control and Prevention in Atlanta, Georgia.
The viruses were grown in MDCK cells after being infected in roller bottles. Infection was done
by diluting the virus 1:1,100 in an infection media. Our flu infection medium consisted of: MEM
(HyClone CAT# SH30024.02), 1 ml of Gentamycin (Sigma CAT# G1397), 10 U/ml of Trypsin
(Sigma CAT# T6567), and 1 µg/ml EDTA (Sigma CAT# E9884).

2.2 Virus Inactivation

The virus was inactivated by Binary Ethylenimine (BEi). This was done by mixing 2Bromoethylamine

hydrobromide (BEA) (Sigma) with 0.2 M of NaOH in sterile water and

incubated for approximately one hour at 37°C +/- 2° C. This results in a binary ethylenimine
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(BEi) product. The BEi was then added to the virus at a ratio of one part of inactivating agent to
nine parts of virus suspension. The final concentration of BEi was 10.0 mM. The virus-BEi
mixture was then slowly stirred at 24°C +/- 1°c for 12 hours . We removed 20 ml samples every
30 minutes for the first 7 hours, and then hourly until 12 hours. The BEi-Virus solution was
neutralized by adding 1.0 M sodium thiosulfate, and the pH was brought to 7.2 by adding 1.0 M
HCI. The inactivated virus was then filtered through a Pellicon XL Cassette {Biomax l00KDa Cat#
PXBl00VS0) and put into 1 ml aliquots and stored at -80°C.

2.3 Column Chromatography

Inactivated influenza samples were passed through columns
containing resins Capto Q and Capto 700, and then collected after
buffer was added to the columns. The columns were initially washed
with a phosphate buffer followed by 150 ml of the BEi inactivated
virus. After the virus solution had been added to the columns they
were washed again with the phosphate buffer. 100 ml increments
of KCI containing phosphate buffers were added to each column.

Figure 6: Columns used for

column chromatography .

The columns were washed a third time and final eluates were
collected.

Columns contain Capto Q or
Capto700 resin.
Photo taken in lab

2.4 Bradford Protein Assay
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After inactivated influenza samples were taken
from the column, a Bradford Protein Assay was used to
evaluate total protein concentration. The inactivated
influenza samples were compared to a standard
containing Bovine Serum Albumin that ranged from Oto
2000 µg of protein.

Figure 7: Plate used for a Bradford

Protein Assay. Samples were placed
on the bottom 4 rows. Bovine
Serum Albumin control was placed
in the top right corner .

2.5 SDS Page

Photo taken in lab

Once protein concentrations were determined, selected samples were passed through a
7.5% precast polyacrylamide gel. An electrical current of 200 V was applied for 10 minutes and
then reduced to 150 V for 40 additional minutes. Total run time was 50 minutes.

2.6 Gelatin

Two different gelatins were used. The first was Gelatin from Porcine Skin (G9136-10 µg
Type A lyophilized powdery-irradiated

BioXtra Sigma). The second gelatin used was Porcine

Skin Gelatin (CAT# GELP12-N-10 Lot# SX0018 Alpha Diagnostic Intl. Inc).

2. 7 Sample Preparation

Inactivated influenza samples were tested on four different variables : Viral protein
concentration, temperature, time and gelatin concentration. Using an HA assay, the original
viral protein concentration from our BEi inactivated stock was found to be 2.8 mg/ml. We used
this stock to test protein concentrations at lmg/ml and 0.3 mg/ml. Our gelatin concentrations
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were tested as both percent by total protein concentration, as well as percent by total volume .
Our gelatin percentages were 0.3%, 1%, 3%, and 10%. Temperature variables were 45°C, 52°C,
and 60°C. Each sample was also made for the following time intervals: 1 min , 5 min , 10 min, 20
min, 40 min, 60 min, 120 min, 240 min, 300 min and 360 min. Inactivated influenza samples
were prepared to a volume of 500 µI per sample. Two controls were utilized: the first was BEiinactivated virus with no gelatin, and the other was BEi-inactivated virus with 3% of albumin by
protein concentration/volume

.

When testing the gelatin percent by total protein, we used the Type A lyophilized
powder (y-irradiated BioXtra) from Sigma. The gelatin stock was prepared at 1 mg/ml by mixing
10 mg of the lyophilized gelatin with 10 ml of phosphate buffered solution (PBS). Table 1 shows
the volumes that were used to make the samples at a total viral protein concentration of 1.0
mg/ml. Table 2 shows the volumes that were used to make samples at a total viral protein
concentration of 0.3 mg/ml.

It was found that the gelatin concentrations were not sufficiently high , so inactivated
influenza samples with gelatin by percent of total volume were made. Porcine Skin Gelatin
(CAT# GELP12- N- 10 Lot# SX0018 Alpha Diagnostic Intl. Inc) was diluted to 200 mg/ml by mixing
1 gram of gelatin with 5 ml of PBS.As it has previously been demonstrated that optimal viral
protein is at 0.3 mg/ml , samples of gelatin by percent of total volume were made with only 0.3
mg/ml of viral protein. Table 3 shows the volumes that were used to make these samples .
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Table 1: Inactivated influenza sample volume preparation of 1.0 mg/ml viral protein
concentration with gelatin by percent of total protein concentration

10%

Amount of BEiInactivated Virus
added from stock
(in µI)
167

3%

167

286

47

1%

167

317

16

0.3%

167

328

5

Gelatin by% of total
protein
concentration

Amount of PBS
added (in µI)

Amount of Gelatin
added from stock
(in µI)

193

140

0%*
167
333
0
Control
3% Albumin*
167
286
47* * of Albumin
Control
* Following samples contained NO gelatin but were used as controls
** 47 µI added were of Albumin NOT gelatin

Table 2: Inactivated influenza sample volume preparation of 0.3 mg/ml viral protein
concentration with gelatin by percent of total protein concentration

10%

Amount of BEiInactivated Virus
added from stock
(in µI)
55

3%

55

398

47

1%

55

429

16

0.3%

55

440

5

0%*
Control
3% Albumin *
Control

55

445

0

55

398

47 of Albumin **

Gelatin by % of total
protein
concentration

Amount of PBS
added (in µI)

Amount of Gelatin
added from stock
(in µI)

305

140

* Following samples contained NO gelatin but were used as controls
** 47 µI added were of Albumin NOT gelatin
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Table 3: Inactivated influenza sample volume preparation of 0.3 mg/ml viral protein
concentration with gelatin by percent of total volume

Gelatin by % of total
volume
10% {100 mg/ml)
3% (30 mg/ml)
1% (10 mg/ml)
0%*
Control
3% Albumin *
Control

Amount of BEiInactivated Virus
added from stock
(in µI)
55
55
55

Amount of PBS
added (in µI)

Amount of Gelatin
added from 200
mg/ml stock (in µI)

195
362
420

250
83
25

55

455

0

55

362

83 of Albumin **

* Following samples contained NO gelatin but were used as controls
** 83 µI added were of Albumin NOT gelatin

2.8 Accelerated Stability Test

The accelerated stability test was performed by placing inactivated influenza samples in
water baths and removing them after a set period of time. Water baths were set at 45°C, 52°C
and 60°C. Samples were removed from the water baths at the following intervals : 1 min, 5 min ,
10 min, 20 min, 40 min, 60 min , 120 min, 240 min , 300 min and 360 min. Once samples were
collected, they were placed immediately in a -80°C freezer until further tested.

2.9 Hemagglutinin (HA) Assay

50 µI of PBSwas added to each well of a round bottom 96-well micro-titer plate. In the
first row 50 µI of the test sample was added , and serially diluted by transferring 50 µI from the
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previous well to the successive well and so on. 50 µI of a

0.5% turkey red blood cell (RBC)suspension was added to
each well on the plate. Cell and virus controls were added
to the same plate. After viral sample addition, plates were
incubated at room temperature. Wells that contained viral
proteins, caused the red blood cells to form a lattice work
and stay in suspension. Wells without any viral proteins
formed "buttons" at the bottom of the well where the red

Figure 8: Microtiter plate on

which hemagglutinin assaywas
performed. Wells with red dots
show no viral proteins, while
wells with no dots indicate
hemagglutination has occurred.
Photo taken in lab

blood cells clumped due to gravity. Titers were recorded after 35 minutes. HA units were
expressed as the reciprocal of the maximum dilution of virus that resulted in complete
agglutination.

2.10 Neuraminidase {NA) Assay

Viral NA activity was assessed using a commercially available kit (NA-Star"lnfluenza
Neuraminidase Inhibitor Resistance Detection Kit, Applied Biosystems, Foster City, CA} in 96well solid white microplates. Inactivated influenza samples were serially diluted using a 1:2
dilution with the NA-Star Assay Buffer. NA-Star Substrate was then prepared by making a

1:1000 dilution in the NA-Star Assay Buffer. 10 µI of the diluted substrate were then added to
each of the wells. The plate was incubated at 37° C for 20 minutes. After incubation the NA
activity was evaluated using a Centro LB 960 luminometer (Berthold Technologies) for 0.5 sec
immediately after addition of NA-Star" accelerator solution . NA activity was determined by
plotting percent chemiluminescent counts versus log10of the NA dilutions.
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Results

3.1 Hemagglutinin (HA) Assay for Column Chromatography

Hemagglutinin

I

Content
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Figure 9: Graph shows the HA value versus the Elution Buffer in Molarity. The blue line

represents samples that were collected from the column containing the Capto Q resin on the
28th of September 2013. The orange line represents samples collected on the 2nd of November
2013 .

Figure 9 shows HA concentrations

from samples taken from the column containing the

Capto Q resin. There was a peak of hemagglutinin
September

in the 0.2M eluates collected on the 28 of

2013.
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Figure 10: Graph shows the HA value versus the Elution Buffer in Molarity. The blue line

represents samples that were collected from the column containing the Capto 700 resin on the
28th of September 2013. The orange line represents samples collected on the 2nd of November
2013.

Figure 10 shows the eluates collected from the column containing the Capto 700 resin.
The graph displays the concentration of the viral hemagglutinin protein. The data collected
from the 28 of September 2013 suggests that the viral protein did not bind to the column, but
rather flowed through the column .

3.1 Bradford Protein Assay for Column Chromatography
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Figure 11 comes from the Bradford Protein Assay which shows the total protein
concentration

present in the eluates collected. This assay showed a peak in protein

concentration . When comparing this graph with figure 9, one can see that the protein peak
corresponds to the hemagglutinin

peak concentration.
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Figure 11: Graph shows the total protein concentration from each of the eluates collected from

the column. The blue line represents samples that were collected from the column containing the
Capto Q resin on the 28th of September 2013. The orange line represents samples that were
collected on the 2nd of November 2013.
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Figure 12 shows the total protein concentration

present in the eluates collected from

the Capto 700 column . This graph indicates a similar peak of total protein concentration
both occasions in which the column was run. There does not seem to be a correlation
the total protein concentration

and the hemagglutinin

on
between

content (Figure 10) from the eluates

collected from the Capto 700 resin.
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3.3 SOS Page for Column Chromatography

Figure 13 is of an SDS gel that shows a
single band of protein that was identified

at
Figure 13: SOSPage of eluates collected

approximately
identified

60kDa. The fact that the band was

after the pt phosphate buffer wash

from columns. A faint band can be seen
coming from the ist phosphate buffer wash
at around 60 KDa.
Photo taken in lab
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suggests that either the viral protein did not stick to the column, or that the protein visible on
the gel was due to a contaminant (possibly bovine serum albumin.)

As only one band of

protein was visible, a more sensitive dye will be needed to detect lower concentrations of
protein .

3.4 Hemagglutinin (HA) Assay for Accelerated Stability Test

Figures 14- 16 show the HA results from the accelerated stability test with a viral protein
concentration of 1.0 mg/ml. Figure 14 shows samples that were placed in a water bath at 60°C.
The results show, that the temperature was too high, denaturing the viral proteins at all gelatin
concentrations.
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Figure 14: Graph shows the HA concentrations

of samples taken from 60°C

water bath at different intervals . As shown in the graph, all viral proteins were
denatured after 10 minutes indicating that our water bath temperature

was

too high .
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Figure 15 shows the HA concentrations of samples taken from a 45°C water bath at
different time intervals. This shows that there no difference of HA was observed between the
samples, suggesting that our water bath temperature was too low.
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Figure 15: Graph shows the HA Concentrations of samples taken from 45°C water bath at

different intervals.

Figure 16 shows the HA concentrations of samples taken from a 52°C water bath at
different time intervals. The graph shows a drop in viral protein concentration after a set period
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Figure 16: Graph shows the HA concentrations of samples taken from 52°C

water bath at different intervals. There is a drop in hemagglutinin
concentration around 60 minutes indicating S2°C as an optimal temperature
for accelerated stability test .

of time, indicating that 52°C is optimal for our accelerated stability test. The graph also shows
that no difference in stability was observed between the different gelatin concentrations .

After looking at our results for the accelerated stability tests with a protein
concentration of 1.0 mg/ml, we repeated our accelerated stability tests with a protein
concentration of 0.3 mg/ml. Figure 17 shows the HA concentrations of those samples. While we
saw some differences in our inactivated influenza samples, there was no evidence that gelatin
extended the stability of the vaccine. The graph also show that there was not a drop in
hemagglutinin in our control , suggesting that the temperature was too low to cause
denaturation for the time intervals set.
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HA Concentration at 45° with a 0.3 mg/ml
Viral Protein Concentration
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Figure 17: Graph shows the HA concentrations of 0.3 mg/ml viral protein

samples taken from a 45°C water bath. While there is variance in the
samples, there is not a difference between the values to suggest that any
sample had an increase in stability.
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Figure 18: HA concentrations of 0.3mg/ml viral protein samples taken from a

52° C water bath. Despite variance between HA values in samples during the
first 100 minutes, no difference in viral protein stability can be seen.
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As we did not see a decrease in HA from the 45° C water bath, we tested the 0.3 mg/ml
viral protein samples at 52

°c.Once again there

was no significant difference between the

inactivated influenza virus samples (Figure 18) to say that the gelatin had an effect on the
stability of the viral proteins.

As no stabilizing effect could be seen from the gelatin, we hypothesized that the gelatin
concentrations were too low . We increased our gelatin by using a percent by total volume. As
we had found that 52°C was the optimal temperature for our tests, we performed an
accelerated stability test with gelatin by percent of total volume at 52°C. As figure 19 shows
there was yet again no difference between our samples and the control.
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Figure 19: HA concentrations of samples containing a 0.3 mg/ml viral protein

concentration . The gelatin samples are 10%, 3%, 1%, and 0% by total volume .
Samples were taken from a 52° C water bath.
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As no differences in vaccine stability could be seen between our samples and our
control, we hypothesized that the gelatin might be interfering with the red blood cells used in
our hemagglutination assay. To test this, we took samples of 0.3mg/ml viral protein that were
not placed in water baths and performed an HA on them. As none of the inactivated influenza
samples had been exposed to elevated temperatures, the estimated HA was around 258. The
gelatin was measured as percent by total volume using 0.5%, 1%, 2%, 3%, and 4%. As figure 20
shows, our hypothesis was confirmed that the gelatin was interacting with the assay and
interfering with our results.
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Figure 20: HA concentrations of samples containing a 0.3 mg/ml viral

protein concentration. None of the samples were exposed to elevated
temperatures, and were expected to have an HA value of 258 . As the graph
shows. the gelatin seems to affect the HA values of the assav.

3.5 Neuraminidase {NA) Assay for Accelerated Stability Test

As gelatin interfered with the results of our HA assay, a NA assay was performed on samples
containing a 0.3 mg/ml viral protein concentration. Inactivated influenza samples contained 1%,
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3%, and 10% gelatin by total volume and were placed in a water bath at 52°C. NA activity was
determined by plotting percent chemiluminescent counts versus log10of the NA dilutions.
Graphs representing each time interval inactivated influenza vaccine was removed from the
water bath. Figures 21-28 show the results of the neuraminidase activity .

Figures 21-28 show significant differences in chemiluminescence between gelatin samples and
the control were seen within 10 minutes of exposure to elevated temperatures. The 3% gelatin
sample has around a 10,000 fold increase in neuraminidase activity than the control after 240
minutes.
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Figure 21: Neuraminidase activity of samples containing 0.3

mg/ml viral protein concentration after exposure to S2°C
water bath for 1 minute. Graph shows chemiluminescence vs
NA dilution

Figure 22: Neuraminidase activity of samples containing 0.3

mg/ml viral protein concentration after exposure to S2°C
water bath for 5 minutes. Graph shows chemiluminescence
vs NA dilution
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Figure 24: Neuraminidase activity of samples containing 0.3
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Figure 27: Neuraminidase activity of samples containing 0.3
mg/ml viral protein concentration

after exposure to S2°C

Figure 28: Neuraminidase activity of samples containing 0.3
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Conclusions
4.1 Column Chromatography

The results from our column chromatography study showed that a peak prote in
concentration appeared to correlate with peak HA content in both columns (Figures 11 and 12).
This suggests that little protein purification has occurred. A band of 60 KDa protein was
identified by the SDS-PAGEfrom the l5 1 phosphate buffer wash (figure 13). Because the HA
assay identifies viral proteins in later eluates (Figure 9), the datum suggests that the band of
protein is a contaminant and not the desired viral protein . It is hypothesized that the sensitivity
of the Simply Blue dye used was too low . A more sensitive dye could be used, such as a silver
stain, to ident ify any remaining proteins in the sample .

As we were not able to identify our protein of interest with the column
chromatography , our results for the column chromatography still remains inconclusive . Such
purification is theoretically possible , but more tests are required to achieve this.

4.2 Hemagglutinin (HA) Assay for Accelerated Stability Test

As shown in figures 14-20, there was no significant difference in the HA activity between
the gelatin samples and the control. It was confirmed that gelatin was interfering with the HA
assay by performing an HA on samples that had not been exposed to elevated temperatures
(Figure 20). Since none of the sample had been exposed to elevated temperatures similar HA
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values were expected. The results show that only the control, albumin, and 0.5% gelatin
samples had recordable HA values.

Since the exact mechanism for the gelatin interference is unknown, I hypothesize that
the gelatin could be causing some form of aggregation with the blood cells. It is known that
collagen is a main stimulant for platelet aggregation. As the body is full of redundancies and
multiple pathways, I hypothesize that the collagen could have caused agglutination in the
erythrocytes th at were used .

4.3 Neuraminidase (NA) Assay for Accelerated Stability Test

Our results from figures 21-28 show that viral protein stability was achieved by the use
of gelatin. The 0.3% gelatin sample was shown to have approximately 10,000 fold increase in
NA activity. Such increased activity suggests that gelatin could be used as an effective vaccine
stabilizer.

Discussion
The cold chain has been the largest obstacle in distributing vaccines around the world.
Because vaccines must be kept at low temperatures, many areas of the world struggle to keep
the vaccine potency throughout the transportation

process . If a vaccine stabilizer was used,

vaccines could be distributed at room temperature without losing vaccine potency . Our results
have shown that gelatin could be used as an effective vaccine stabilizer for the influenza HlNl
BEi inactivated virus.
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The exact stabilizing mechanism of gelatin is still unknown. Based on the findings two
hypothesis can be suggested . The first has to do with the structure of gelatin. As gelatin is
simply denatured collagen, there is a meshwork of tiny pores that are formed from the
different lengths of collagen strands. This could possibly form small nanoscale environments
that are optimal for the viral particles . Such stabilization has been seen in the application of silk
as a stabilizer (Zhang et al., 2012).

Another hypothesis for gelatin's stabilizing ability, could be from binding of the gelatin
to the virus. According to Liska et al. (2007) gelatin provides non covalent binding to virus
particles that is non-specific. It is believed that this binding could enhance the stability of the
viral particles. As we can only hypothesize the stabilizing mechanisms of collagen, more
research is required .

While it has been shown that gelatin can increase the stability of a vaccine, it should be
noted that one cannot inject a patient with the gelatin still inside. Many studies have shown
that endogenous gelatin can cause serious allergic responses (Sakaguchi et al., 2000). Because
of this danger, we have collaborated with our partner Dr. Michael Seungju at the University of
Utah. Dr. Seungju has developed a peptide that binds to gelatin. With this peptide, we could
use gelatin as a stabilizer and then extract it from the vaccine after successful transportation.
This could revolutionize the way vaccines are shipped around the world.

The cold chain is one of the most difficult problems we face in vaccine distribution
today. 80% of funds for vaccine production is spent on the effective transportation

of the

vaccines. With the use of gelatin as a vaccine stabilizer, we can eliminate the cold chain
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altogether. This could not only increase the accessibility of vaccines across the world, but has
the potential to save millions of lives each year.
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Honor's Thesis
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Being a biology major, my classes have been very science oriented . There did not seem
to be very much overlap in the humanities programs . My involvement with UNICEF, however, has made
me very interested in areas such as global health . I found it difficult at times to combine my interests in
UNICEFwith my biology degree . It felt as if they were two separate aspects of my life that were
completely polar from each other.

My capstone project was an opportunity to be able to bridge all of my interests during my
college career into a single reflective project . Working at the Institute for Antiviral Research, I was
introduced to Dr. Bart Tarbet . Dr. Tarbet has worked with vaccine manufacturing for a number of years,
as well as BARDA. After talking with him, I discovered that we shared a common interest in global
health . I found this as an opportunity to apply my interests from UNICEFwith projects that I was already
working on in the lab .

As I worked with Dr. Tarbet for over two years, I was able to learn a vast amount of assays and
procedures . I started off basic, learning how to do something as simple as culturing cells and aseptic
technique . Towards the end of my college career, I was able to do all of my own viral dilutions and
sample preparations .

Of all of the lessons that I have learned from my project, the greatest is probably persistence.
Many times our tests would fail and we would not get the data we wanted . I constantly had to go back
and evaluate what I did, and find ways to improve . There were many 12 hour Saturdays spent in the lab,

only to find that our results did not work. This was frustrating at times, but it taught me that there is no
such thing as a "failed" experiment. You take your results, and learn what you can do better.

There was a time during my undergraduate career, that I had to take a hiatus form my research
in order to study for my MCAT. As I was applying for medical school, I was finding it difficult to spend the
amount of time I needed to in the lab. This hiatus was strenuous on my project, and it is reflective on
our column chromatography data. As the project required more time, we were not able to get the
results we wanted. Once I finished my MCAT I had intended on returning to the column chromatography
project but we were presented with a more promising alternative; vaccine stabilization.

While I found the vaccine stability project to be very exciting, it also came with many failed
results . We had read a number of different journals that had said vaccine stability could be achieved
through gelatin stabilization, yet we were not able to reproduce these results . I found myself constantly
looking at our variables and seeing what we needed to change. This was anything from our temperature
to our viral protein concentration.

My proudest moment, however, came from looking at another "failed" run and realizing that
was not due to our error. After looking at the results closely, it became clear to me that the gelatin had
to have been interfering with our assay. We made a hypothesis, and ran a tests to see if we were
correct . One of the most gratifying feelings I have ever felt, was getting our results and seeing that it
supported our hypothesis. While I have applied the scientific method many times in my college career,
this was the first time that it was not laid out for us in a lab manual. I felt like I was a pioneer in a new
field, or an explorer discovering something for the first time.

After taking our results, we were able to evaluate different membrane protein found on the
virus. At this point, it was like something just clicked. Our results started coming back beautiful. I felt

giddy to finally, after two years, start getting results that were working. To anyone else, it might just
look like lines on a graph, but to me it is a reflection of years of dedication and hard work.

My honor's capstone thesis has been one of the most rewarding achievements I have done in
my entire undergraduate career. This project has pushed me farther than any other class I have taken. I
have spent countless hours in a lab and reading journals, but it has been worth every second of it.
Looking at the finished project, I am proud of how difficult it was.

If I could give advice to anyone starting a thesis, I would say this: Find something you are
passionate about. The amount of time spent on this project was far more than a three credit class, but
because I was invested in the results it never felt like a burden. By taking pride in your project , it will
push you to do more than what is merely required of you. By thinking about your thesis early on in your
undergraduate career, you can identify a project that will reflect not only what you did during your time
at USU, but who you became as a person.

I am grateful to have had a mentor that was able to council me and help me to do more than I
thought I ever could . Dr. Tarbet pushed me to strive for perfection. While at times I thought he was
being nitpicky on little things, I have realized that he was helping me to be the best that I could be. I am
also grateful for all of the faculty that have worked with me on my committee . I felt that the faculty on
my project genuinely cared about me and my future plans. I do not think I would have gotten to know
them at this level if it had not been for my project. This has project has truly been a capstone that
served as an emotional finale for my time here at Utah State University. Thank you for the opportunity!

Autobiography

Jorgen graduated from Bear River High School in 2008. He initially started his
undergraduate career at Southern Utah University majoring in theater. After serving an LDS
mission in Antananarivo, Madagascar, Jorgen transferred to Utah State University and changed
his major to Biology with a minor in Chemistry.

In 2012 Jorgen started the UNICEFclub at Utah State University. The club focuses on
educating students about global poverty, advocating for UNICEF, and raising funds to help
children in need. In 2014 Jorgen was one of six students in the nation to serve as a national
campus initiative leader for the US Fund for UNICEF. During that time, Jorgen oversaw 16
universities in the Midwest, and coordinated with the US Fund for UNICEF in New York City.

Jorgen has been actively involved on campus working as a teaching assistant for six
semesters in Human Anatomy, Human Dissection, as well as Advanced Human Physiology.
Jorgen has also served as a camp facilitator for the Hugh O' Brian Youth (HOBY) Leadership
camps. From 2012-2014 Jorgen worked as a volunteer in the Logan regional emergency room.

From 2013 -2015 Jorgen worked as the lead animal technician for the Institute for
Antiviral Research at Utah State University . During that time he has assisted in a number of
different in vivo studies, as well as in vitro . During his time with the Institute for Antiviral
Research, Jorgen started working with Dr. Bart Tarbet with research projects that he felt related
to his passion with UNICEF and global health. Jorgen has worked with Dr. Tarbet for over four
months leading up to his thesis.
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Jorgen has just recently been accepted to medical school at Penn State Milton Hershey
Medical School, as well as the University of Utah. He plans on pursuing *- a medical career in
Infectious Diseases with an emphasis in Pediatrics .
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